Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
In view of the existence of malignant ascites in patients with advanced pancreatic cancer, we
put forward the heat abdominal cavity perfusion chemotherapy combined albumin paclitaxel and
gemcitabine compared with albumin paclitaxel and gemcitabine prospective clinical study, to
assess abdominal albumin hot perfusion chemotherapy combined control of ascites and taxol in
improving patients' quality of life, survival, exploring the feasibility of celiac hot
perfusion chemotherapy combined albumin paclitaxel and side effects.